Viatris Inc

ITEM 1A. RISK FACTORS

Except as set forth below,  there have been no material changes in the Companys ris risk factors from those  disclosed in Viatris 2024 Form 10-K.

The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business, as well as any retaliatory actions with respect to such actions, could have a material adverse effecPart II, Item 1A of the Companys Quarterly Report on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price.

The U.S. has recently imposForm 10-Q for the quarter ended significant tariffs on imports from other countries, which have prompted retaliatory measures from several countriesMarch 31, 2025, which may further escalate, and impact our cost of doing business. While pharmaceutical products are currently excluded from the baseline and reciprocal tariffs imposed by the U.S., the current U.S. administration has expressed an intent to impose tariffs on pharmaceutical imports in the near future.

The imposition of adopted, new or proposed tariffs, trade restrictions or domestic sourcing requirements on pharmaceutical imports, including but not limited to products, ingredients, and inputs (such as API), could result in increased costs of goods and prices, disruptions to our supply chain, manufacturing delays, supply shortages, and adverse impacts to clinical trials. These measures could also result in decreased profit margins on certain of our products, particularly within our generics portfolio. Decreased or negative profit margins have in the past, and could in is hereby incorporated by reference into this Part II, Item 1A of this Form 10-Q, the future, make the production of certain of our products unsustainable, thereby reducing our net sales as well as access for patients. In addition, we may be restricted in our ability to adapt to these impacts and challere have been no material changes due to, among other things,in the terms of our current customer, supply or distribution agreements, or the need to obtain regulatory approval prior to making any changes to our manufacturing locations, processes or suppliers. Future tariffs, trade agreements, or domestic sourcing requirements, as well as potential exemptions, could also provide our competitors with an advantage.

The impact of any adopted, new or proposed tariffs, trade restrictions or domestic sourcing requirements on our business is subject to a number of factors that we cannot predict, including, but not limited to, the scope, nature, amount, effective date and duration of any such measures. Furthermore, general uncertainty related to adopted, new or potential tariffs, trade restrictions and domestic sourcing requirements has in the past reduced and could in the future further reduce global economic activity, thereby resulting in additional adverse impacts to us.

63Companys risk factors from those disclosed in Viatris 2024 Form 10-K.

75

Any of the risks described above could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price.